Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna’s Ocular Therapeutix OCUL Stock Holding History

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,500	Closed	-$455K	–	83
2021 Q3	$455K	Buy	45,500 +13,500	+42%	+$152K	0.11%	47
2021 Q2	$454K	Buy	+32,000	New	+$486K	0.1%	44

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's OCUL Position: Q4 2021 in Review

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 45,500 shares — an estimated $455K sold.

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna first reported a position in OCUL in Q2 2021 and held it in 2 quarters. The position peaked at $455K in Q3 2021. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna sold 45,500 Ocular Therapeutix shares in Q4 2021, an estimated $455K.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna first reported a position in Ocular Therapeutix in Q2 2021 and held it in 2 quarters.
Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's Ocular Therapeutix position peaked at $455K in Q3 2021.
140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna's 13F filing for Q4 2021, filed 2 Sep 2025.